Immunome Surges 13.4% on Volatility-Fueled Rally—What’s Driving the Biotech Breakout?

Summary
• Immunome (IMNM) rockets 13.4% to $19.38, nearing 52-week high of $19.48
• Intraday range spans $17.0 (low) to $19.48 (high), signaling sharp reversal
• Options chain surges with 23 contracts trading, including $20 call options seeing 9,072 turnover
• Biotech sector leader Amgen (AMGN) gains 1.83%, but Immunome’s move lacks direct sector linkage

Immunome’s explosive intraday rally has ignited market attention, with the stock surging 13.4% to $19.38 amid heightened volatility. While the biotech sector remains mixed, Immunome’s performance defies broader trends, driven by technical momentum and speculative options activity. Traders are now scrutinizing key resistance levels and options positioning to gauge sustainability.

Volatility and Technical Reversal Fuel Sharp Uptick
The 13.4% surge in Immunome’s stock price is primarily attributed to a short-term technical reversal and speculative options activity. The stock’s price action shows a sharp rebound from the lower Bollinger Band ($14.95) to near the upper band ($19.62), indicating a breakout from a prolonged consolidation phase. The RSI (46.75) and MACD (-0.1245 histogram) suggest a shift from bearish to neutral momentum, while the 30-day moving average (16.93) and 200-day average (10.57) highlight a long-term bullish divergence. Despite no company-specific news, the options chain reveals aggressive call buying, particularly for the $20 strike price expiring December 19, with 9,072 contracts traded and 44.83% price change ratio, signaling strong short-term bullish sentiment.

Options and ETF Playbook: Capitalizing on Volatility and Breakouts
• Technical Indicators:
- 200-day average: $10.57 (well below current price)
- RSI: 46.75 (neutral, suggesting potential for further upside)
- MACD: 0.7858 (bullish crossover with signal line at 0.9103)
- Bollinger Bands: Price at $19.38 (near upper band at $19.62)
- Support/Resistance: 30D support at $17.49, 200D support at $8.70

Trading Setup: The stock’s breakout above the 30-day moving average and proximity to the 52-week high ($19.48) suggest a high-probability short-term trade. Key levels to watch include $19.48 (52W high) and $17.28 (middle Bollinger Band). The RSI’s neutral reading and MACD’s bullish crossover indicate potential for continued momentum, though the negative histogram (-0.1245) warns of possible short-term exhaustion. No leveraged ETF data is available, but the biotech sector’s mixed performance (Amgen up 1.83%) suggests Immunome’s move is driven by individual technicals rather than sector-wide trends.

Top Options Picks:
1. IMNM20251219C20 (Call, $20 strike, Dec 19 expiration)
- Implied Volatility: 255.51% (high)
- Lverage Ratio: 4.85%
- Delta: 0.5886 (moderate sensitivity)
- Theta: -0.1403 (high time decay)
- Gamma: 0.0364 (moderate sensitivity to price movement)
- Turnover: 9,072 (high liquidity)
- Payoff (5% upside to $20.35): $0.35/share ($35/contract)
- Why it stands out: High turnover and implied volatility make this contract ideal for capitalizing on a breakout above $20. The moderate delta and high gamma suggest strong responsiveness to price movement, while the high theta indicates urgency for a near-term move.

2. IMNM20251219C19 (Call, $19 strike, Dec 19 expiration)
- Implied Volatility: 249.95% (high)
- Lverage Ratio: 4.51%
- Delta: 0.6224 (moderate sensitivity)
- Theta: -0.1357 (high time decay)
- Gamma: 0.0363 (moderate sensitivity to price movement)
- Turnover: 430 (reasonable liquidity)
- Payoff (5% upside to $20.35): $1.35/share ($135/contract)
- Why it stands out: The $19 strike offers higher leverage for a breakout above $20, with a delta near 0.62 indicating strong directional bias. The high gamma ensures increased sensitivity as the stock approaches the strike price, making it a high-reward option for aggressive bulls.

Aggressive bulls may consider IMNM20251219C20 into a bounce above $20.35, while IMNM20251219C19 offers outsized gains if the 52-week high is breached. Both contracts require tight stop-loss management due to high theta decay.

Backtest Immunome Stock Performance
Here is the event-driven back-test you requested, evaluating Immunome Inc. (IMNM) after every day its closing price surged ≥ 13 % versus the previous close, from 1 Jan 2022 through today.Key take-aways 1. Sample size: 28 surge events were identified over the period 2022-01-03 → 2025-12-03. 2. Short-term edge limited: • Average next-day return: +0.46 % (win-rate ≈ 64 %, but not statistically significant). • 5-day avg return: +2.77 % vs S&P 500 benchmark +1.10 %; significance low. • 10-day avg return: +3.86 % vs benchmark +2.17 %; still statistically insignificant. 3. Medium-term mean reversion: By day 20 the average excess return turns negative (-4.69 % vs benchmark +4.32 %). 4. Volatility & risk: Several events experienced swift give-backs; roughly half the events showed drawdowns >10 % within 10 trading days. 5. Practical implication: Chasing 13 % one-day pops in IMNM has not produced a reliable edge; gains are modest and fade after ~2–3 weeks. A short-term (1-5 day) continuation trade with tight risk controls could be explored, but longer holds underperform the market.Auto-chosen assumptions & why • Event definition: “Close-to-close jump ≥ 13 %” (intraday high vs prior close often unavailable; close-to-close is standard and reproducible). • Back-test horizon: 30 trading days post-event—common window for short/medium-term shock studies; can be adjusted on request. • Benchmark: S&P 500 total-return proxy for relative comparison. Feel free to refine any of these parameters.Click “View Results” below for full interactive statistics (per-day PnL curve, histograms, and individual event drill-downs).Let me know if you’d like deeper diagnostics (e.g., alternative thresholds, different holding horizons, or trade execution rules).

Breakout or Bubble? Key Levels to Watch for Immunome’s Next Move
Immunome’s 13.4% surge hinges on its ability to sustain momentum above $19.48 (52-week high) and confirm a breakout from the Bollinger Band range. The RSI’s neutral stance and MACD’s bullish crossover suggest potential for further upside, but the negative histogram warns of possible short-term exhaustion. Traders should monitor the $19.48 level for a decisive close above it, which could validate the breakout and trigger a rally toward $20.50. Meanwhile, Amgen’s 1.83% gain as the sector leader underscores the biotech sector’s mixed performance, indicating Immunome’s move is driven by individual technicals rather than broader sector trends. Act now: Buy IMNM20251219C20 for a high-liquidity play on the 52-week high breakout, or short-term traders should watch for a pullback to the middle Bollinger Band at $17.28 for a potential reentry.